AVEO missed earnings - kidney cancer treatment too thinly traded
Updated
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Comment
Currently at 618fibretracement
Comment
Full 241% retracement and bounce to 161%. Sign of bouncing cat?Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.